The emerging class of GLP-1 receptor and GIP dual medications, like tirzepatide, semaglutide, and the newly introduced retatrutide, provide significant advances in metabolic management . While all three work https://ghk-cu-copper-peptide359854.imblogs.net/93647158/semaglutide-a-thorough-examination